Comparative Pharmacology
Head-to-head clinical analysis: NYSTATIN TRIAMCINOLONE ACETONIDE versus PENECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYSTATIN TRIAMCINOLONE ACETONIDE versus PENECORT.
NYSTATIN-TRIAMCINOLONE ACETONIDE vs PENECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nystatin is a polyene antifungal that binds to ergosterol in the fungal cell membrane, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
PENECORT is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation, immune responses, and adrenal function.
Apply topically to affected area twice daily for 2-4 weeks.
2.5-5 mg orally once daily; maximum 10 mg/day. Intramuscular: 20-40 mg every 2-4 weeks.
None Documented
None Documented
Nystatin: negligible systemic half-life due to lack of absorption. Triamcinolone acetonide: terminal half-life ~2-5 hours (mean ~3.5 h) after intravascular administration; prolonged in hepatic impairment.
Terminal elimination half-life: 3-4 hours in adults; prolonged in hepatic impairment (up to 8 hours).
Nystatin: negligible systemic absorption; excreted unchanged in feces (~100%). Triamcinolone acetonide: metabolized hepatically; renal excretion of metabolites (~40%) and unchanged drug (<5%); fecal excretion (~60%).
Renal: 60-70% as metabolites, 5-10% unchanged; Biliary/fecal: 20-30% as metabolites.
Category D/X
Category C
Corticosteroid
Corticosteroid